Zoledronic Acid for Osteoporotic Fracture Prevention (ZEST II) (ZEST II)
ZEST II for Osteoporotic Fracture Prevention
Sponsor: National Institute on Aging (NIA)
This PHASE4 trial investigates Osteoporosis, Postmenopausal and Osteoporotic Fractures and is currently completed. National Institute on Aging (NIA) leads this study, which shows 16 recorded versions since 2016 — indicating substantial longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
16 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE4
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE4
-
Oct 2023 — Jul 2024 [monthly]
Completed PHASE4
-
Sep 2023 — Oct 2023 [monthly]
Completed PHASE4
-
Sep 2022 — Sep 2023 [monthly]
Completed PHASE4
Status: Active Not Recruiting → Completed
▶ Show 11 earlier versions
-
Feb 2022 — Sep 2022 [monthly]
Active Not Recruiting PHASE4
-
Feb 2021 — Feb 2022 [monthly]
Active Not Recruiting PHASE4
-
Jan 2021 — Feb 2021 [monthly]
Active Not Recruiting PHASE4
-
Feb 2020 — Jan 2021 [monthly]
Active Not Recruiting PHASE4
-
Jan 2020 — Feb 2020 [monthly]
Active Not Recruiting PHASE4
Status: Recruiting → Active Not Recruiting
-
Aug 2019 — Jan 2020 [monthly]
Recruiting PHASE4
-
Feb 2019 — Aug 2019 [monthly]
Recruiting PHASE4
-
Oct 2018 — Feb 2019 [monthly]
Recruiting PHASE4
-
Jun 2018 — Oct 2018 [monthly]
Recruiting PHASE4
-
Feb 2017 — Jun 2018 [monthly]
Recruiting PHASE4
-
Jan 2017 — Feb 2017 [monthly]
Recruiting PHASE4
First recorded
Jan 2016
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- National Institute on Aging (NIA)
- National Institutes of Health (NIH)
- Susan L. Greenspan
For direct contact, visit the study record on ClinicalTrials.gov .